Amalgamated Bank Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Amalgamated Bank lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.2% in the third quarter, Holdings Channel reports. The institutional investor owned 34,696 shares of the medical research company’s stock after selling 2,283 shares during the period. Amalgamated Bank’s holdings in IQVIA were worth $8,222,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Norden Group LLC bought a new position in IQVIA in the first quarter worth approximately $703,000. GSA Capital Partners LLP bought a new stake in IQVIA during the 1st quarter valued at about $700,000. Advisory Alpha LLC purchased a new stake in shares of IQVIA in the 1st quarter worth $375,000. Duality Advisers LP bought a new position in shares of IQVIA during the first quarter valued at approximately $2,300,000. Finally, Empirical Finance LLC grew its stake in IQVIA by 3.4% in the first quarter. Empirical Finance LLC now owns 6,660 shares of the medical research company’s stock valued at $1,684,000 after purchasing an additional 221 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 3.9 %

Shares of IQVIA stock opened at $221.19 on Thursday. IQVIA Holdings Inc. has a 52-week low of $190.20 and a 52-week high of $261.73. The company has a 50 day moving average of $232.31 and a 200 day moving average of $229.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $40.15 billion, a P/E ratio of 29.03, a P/E/G ratio of 2.15 and a beta of 1.51.

Wall Street Analyst Weigh In

Several analysts have weighed in on IQV shares. Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday. Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft cut their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.